June 21, 2017
Researchers are examining a variety of therapeutic regimens for patients with myeloproliferative neoplasms (MPNs), as well as working to obtain a deeper understanding of the biology of these conditions. This includes investigating combining new biologic agents with FDA-approved therapies in order to improve response rates and quality of life (QOL). Dr. Ellen Ritchie speaks with OncLive regarding ongoing research in this area. Learn more.